Literature DB >> 16944155

Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies.

Sara Kashef1, Mohammad Mehdi Ghaedian, Akbar Rajaee, Abbas Ghaderi.   

Abstract

Dyslipoproteinemia is common in lupus patients. In this study, we investigated the pattern of dyslipoproteinemia in the course of active systemic lupus erythematosus (SLE) in possible association with anti-double-stranded DNA (anti-dsDNA) antibodies. Forty-six lupus patients under 45 years old who fulfilled the American College of Rheumatology revised criteria for the classification of SLE were selected. The exclusion criteria were renal failure, nephrotic syndrome, thyroid or liver disease, diabetes mellitus, obesity, pregnancy and taking drugs that induce dyslipidemia. Disease activity was measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Comparison of the lipid profiles, between active and inactive groups determined high levels of serum TG and VLDL and low levels of serum HDL in active group in comparison with inactive group (P < 0.05). The results indicated that the levels of TG and VLDL were significantly elevated in the patients with positive anti-dsDNA (P < 0.05). Although, the mean of serum HDL levels was also lower in patients with positive anti-dsDNA, the difference was not significant. This pattern of dyslipoproteinemia in active SLE may be associated with the autoimmune mechanisms especially in relation to the presence of anti-dsDNA antibodies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16944155     DOI: 10.1007/s00296-006-0195-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  28 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies.

Authors:  E F Borba; E Bonfá
Journal:  Lupus       Date:  1997       Impact factor: 2.911

3.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  J Delgado Alves; P R J Ames; S Donohue; L Stanyer; J Nourooz-Zadeh; C Ravirajan; D A Isenberg; J Noorouz-Zadeh
Journal:  Arthritis Rheum       Date:  2002-10

6.  Inhibition of lipoprotein lipase activity by a monoclonal immunoglobulin in autoimmune hyperlipidemia.

Authors:  J L Beaumont; M Berard; M Antonucci; B Delplanque; R Vranckx
Journal:  Atherosclerosis       Date:  1977-01       Impact factor: 5.162

7.  Dyslipoproteinemia in pediatric systemic lupus erythematosus.

Authors:  N T Ilowite; P Samuel; E Ginzler; M S Jacobson
Journal:  Arthritis Rheum       Date:  1988-07

8.  Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases.

Authors:  C Ehnholm; K Aho; J K Huttunen; E Kostiainen; K Mattila; J Pakkarainen; K Cantell
Journal:  Arteriosclerosis       Date:  1982 Jan-Feb

9.  Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids.

Authors:  W H Ettinger; A P Goldberg; D Applebaum-Bowden; W R Hazzard
Journal:  Am J Med       Date:  1987-09       Impact factor: 4.965

10.  Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.

Authors:  Elisabet Svenungsson; Iva Gunnarsson; Guo-Zhong Fei; Ingrid E Lundberg; Lars Klareskog; Johan Frostegård
Journal:  Arthritis Rheum       Date:  2003-09
View more
  5 in total

1.  Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.

Authors:  S P Ardoin; L E Schanberg; C Sandborg; E Yow; H X Barnhart; K l Mieszkalski; N T Ilowite; E von Scheven; A Eberhard; D M Levy; Y Kimura; E Silverman; S L Bowyer; L Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L K Jung; L Imundo; J B Soep; A M Reed
Journal:  Lupus       Date:  2010-10       Impact factor: 2.911

2.  Dyslipidaemia in rheumatological autoimmune diseases.

Authors:  Tracey E Toms; Vasileios F Panoulas; George D Kitas
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

Review 3.  High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy.

Authors:  Sang Yeop Kim; Minzhi Yu; Emily E Morin; Jukyung Kang; Mariana J Kaplan; Anna Schwendeman
Journal:  Arthritis Rheumatol       Date:  2019-11-26       Impact factor: 10.995

4.  Role of resistin as a marker of inflammation in systemic lupus erythematosus.

Authors:  Katarina Almehed; Helena Forsblad d'Elia; Maria Bokarewa; Hans Carlsten
Journal:  Arthritis Res Ther       Date:  2008-01-30       Impact factor: 5.156

5.  Clinical significance of non-thyroidal illness syndrome on disease activity and dyslipidemia in patients with SLE.

Authors:  Xin Zhang; Lirong Liu; Xiaolei Ma; Wei Hu; Xue Xu; Saisai Huang; Bingzhu Hua; Hong Wang; Zhiyong Chen; Lingyun Sun
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.